The genomic landscape of prostate cancer

International Journal of Molecular Sciences

Volumn 14, Issue 6, 2013, Pages 10822-10851

  Spans, Lien ^a   Clinckemalie, Liesbeth ^a   Helsen, Christine ^a   Vanderschueren, Dirk ^a   Boonen, Steven ^a   Lerut, Evelyne ^b   Joniau, Steven ^c   Claessens, Frank ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Copy number changes; Gene fusions; Long non coding RNAs; Methylation; microRNAs; Next generation sequencing; Prostate cancer; Single nucleotide polymorphisms; Single nucleotide variants

Indexed keywords

ANDROGEN RECEPTOR; DNA; FORMALDEHYDE; GLYCOPROTEIN; LONG UNTRANSLATED RNA; MICRORNA; PARAFFIN; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; TRANSCRIPTOME; UNTRANSLATED RNA;

AVIAN ERYTHROBLASTOSIS ONCOVIRUS; BASE PAIRING; CANCER GENETICS; COPY NUMBER VARIATION; DNA METHYLATION; EPITHELIAL MESENCHYMAL TRANSITION; EXOME; GENE EXPRESSION; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; ONCOGENE; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; UNTRANSLATED REGION; GENETICS; HUMAN GENOME; MALE; METABOLISM; PROSTATE TUMOR;

DNA COPY NUMBER VARIATIONS; DNA METHYLATION; GENOME, HUMAN; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, UNTRANSLATED;

EID: 84878437130     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140610822     Document Type: Review

References (144)

1. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int. J. Cancer 2010, 127, 2893-2917.
2. Cooperberg, M.R.; Moul, J.W.; Carroll, P.R. The changing face of prostate cancer. J. Clin. Oncol. 2005, 23, 8146-8151.
3. Eifler, J.B.; Feng, Z.; Lin, B.M.; Partin, M.T.; Humphreys, E.B.; Han, M.; Epstein, J.I.; Walsh, P.C.; Trock, B.J.; Partin, A.W. An updated prostate cancer staging nomogram (partin tables) based on cases from 2006 to 2011. BJU Int. 2013, 111, 22-29.
4. Kattan, M.W.; Eastham, J.A.; Stapleton, A.M.; Wheeler, T.M.; Scardino, P.T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl. Cancer Inst. 1998, 90, 766-771.
5. D'Amico, A.V.; Whittington, R.; Malkowicz, S.B.; Schultz, D.; Blank, K.; Broderick, G.A.; Tomaszewski, J.E.; Renshaw, A.A.; Kaplan, I.; Beard, C.J.; et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280, 969-974.
6. Choudhury, A.D.; Eeles, R.; Freedland, S.J.; Isaacs, W.B.; Pomerantz, M.M.; Schalken, J.A.; Tammela, T.L.; Visakorpi, T. The role of genetic markers in the management of prostate cancer. Eur. Urol. 2012, 62, 577-587.
7. Lonigro, R.J.; Grasso, C.S.; Robinson, D.R.; Jing, X.; Wu, Y.M.; Cao, X.; Quist, M.J.; Tomlins, S.A.; Pienta, K.J.; Chinnaiyan, A.M. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia 2011, 13, 1019-1025.
8. Reynolds, M.A. Molecular alterations in prostate cancer. Cancer Lett. 2008, 271, 13-24.
9. Demichelis, F.; Setlur, S.R.; Beroukhim, R.; Perner, S.; Korbel, J.O.; Lafargue, C.J.; Pflueger, D.; Pina, C.; Hofer, M.D.; Sboner, A.; et al. Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer 2009, 48, 366-380.
10. Taylor, B.S.; Schultz, N.; Hieronymus, H.; Gopalan, A.; Xiao, Y.; Carver, B.S.; Arora, V.K.; Kaushik, P.; Cerami, E.; Reva, B.; et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18, 11-22.
11. Grasso, C.S.; Wu, Y.M.; Robinson, D.R.; Cao, X.; Dhanasekaran, S.M.; Khan, A.P.; Quist, M.J.; Jing, X.; Lonigro, R.J.; Brenner, J.C.; et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487, 239-243.
12. Berger, M.F.; Lawrence, M.S.; Demichelis, F.; Drier, Y.; Cibulskis, K.; Sivachenko, A.Y.; Sboner, A.; Esgueva, R.; Pflueger, D.; Sougnez, C.; et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470, 214-220.
13. Boyd, L.K.; Mao, X.; Xue, L.; Lin, D.; Chaplin, T.; Kudahetti, S.C.; Stankiewicz, E.; Yu, Y.; Beltran, L.; Shaw, G.; et al. High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer. Genes Chromosomes Cancer 2012, 51, 579-589.
14. Wu, C.; Wyatt, A.W.; Lapuk, A.V.; McPherson, A.; McConeghy, B.J.; Bell, R.H.; Anderson, S.; Haegert, A.; Brahmbhatt, S.; Shukin, R.; et al. Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J. Pathol. 2012, 227, 53-61.
15. Liu, W.; Laitinen, S.; Khan, S.; Vihinen, M.; Kowalski, J.; Yu, G.; Chen, L.; Ewing, C.M.; Eisenberger, M.A.; Carducci, M.A.; et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 2009, 15, 559-565.
16. Cheng, I.; Levin, A.M.; Tai, Y.C.; Plummer, S.; Chen, G.K.; Neslund-Dudas, C.; Casey, G.; Rybicki, B.A.; Witte, J.S. Copy number alterations in prostate tumors and disease aggressiveness. Genes Chromosomes Cancer 2012, 51, 66-76.
17. Rowley, J.D. Chromosome translocations: Dangerous liaisons revisited. Nat. Rev. Cancer 2001, 1, 245-250.
18. Tomlins, S.A.; Rhodes, D.R.; Perner, S.; Dhanasekaran, S.M.; Mehra, R.; Sun, X.W.; Varambally, S.; Cao, X.; Tchinda, J.; Kuefer, R.; et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310, 644-648.
19. Tomlins, S.A.; Mehra, R.; Rhodes, D.R.; Smith, L.R.; Roulston, D.; Helgeson, B.E.; Cao, X.; Wei, J.T.; Rubin, M.A.; Shah, R.B.; et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006, 66, 3396-3400.
20. Donaldson, L.W.; Petersen, J.M.; Graves, B.J.; McIntosh, L.P. Secondary structure of the ETS domain places murine Ets-1 in the superfamily of winged helix-turn-helix DNA-binding proteins. Biochemistry 1994, 33, 13509-13516.
21. Vaarala, M.H.; Porvari, K.; Kyllonen, A.; Lukkarinen, O.; Vihko, P. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: Detection of mutated TMPRSS2 form in a case of aggressive disease. Int. J. Cancer 2001, 94, 705-710.
22. Vaarala, M.H.; Porvari, K.S.; Kellokumpu, S.; Kyllonen, A.P.; Vihko, P.T. Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues. J. Pathol. 2001, 193, 134-140.
23. Perner, S.; Mosquera, J.M.; Demichelis, F.; Hofer, M.D.; Paris, P.L.; Simko, J.; Collins, C.; Bismar, T.A.; Chinnaiyan, A.M.; de Marzo, A.M.; et al. TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am. J. Surg. Pathol. 2007, 31, 882-888.
24. Mosquera, J.M.; Perner, S.; Demichelis, F.; Kim, R.; Hofer, M.D.; Mertz, K.D.; Paris, P.L.; Simko, J.; Collins, C.; Bismar, T.A.; et al. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J. Pathol. 2007, 212, 91-101.
25. Tomlins, S.A.; Laxman, B.; Dhanasekaran, S.M.; Helgeson, B.E.; Cao, X.; Morris, D.S.; Menon, A.; Jing, X.; Cao, Q.; Han, B.; et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007, 448, 595-599.
26. Pflueger, D.; Terry, S.; Sboner, A.; Habegger, L.; Esgueva, R.; Lin, P.C.; Svensson, M.A.; Kitabayashi, N.; Moss, B.J.; MacDonald, T.Y.; et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res. 2011, 21, 56-67.
27. Maher, C.A.; Kumar-Sinha, C.; Cao, X.; Kalyana-Sundaram, S.; Han, B.; Jing, X.; Sam, L.; Barrette, T.; Palanisamy, N.; Chinnaiyan, A.M. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009, 458, 97-101.
28. Esgueva, R.; Perner, S.; Christopher, J.L.; Scheble, V.; Stephan, C.; Lein, M.; Fritzsche, F.R.; Dietel, M.; Kristiansen, G.; Rubin, M.A. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod. Pathol. 2010, 23, 539-546.
29. Han, B.; Mehra, R.; Dhanasekaran, S.M.; Yu, J.; Menon, A.; Lonigro, R.J.; Wang, X.; Gong, Y.; Wang, L.; Shankar, S.; et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: Identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 2008, 68, 7629-7637.
30. Helgeson, B.E.; Tomlins, S.A.; Shah, N.; Laxman, B.; Cao, Q.; Prensner, J.R.; Cao, X.; Singla, N.; Montie, J.E.; Varambally, S.; et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 2008, 68, 73-80.
31. Rickman, D.S.; Pflueger, D.; Moss, B.; VanDoren, V.E.; Chen, C.X.; de la Taille, A.; Kuefer, R.; Tewari, A.K.; Setlur, S.R.; Demichelis, F.; et al. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res. 2009, 69, 2734-2738.
32. Weischenfeldt, J.; Simon, R.; Feuerbach, L.; Schlangen, K.; Weichenhan, D.; Minner, S.; Wuttig, D.; Warnatz, H.J.; Stehr, H.; Rausch, T.; et al. Integrative genomic analyses reveal an androgendriven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013, 23, 159-170.
33. Maher, C.A.; Palanisamy, N.; Brenner, J.C.; Cao, X.; Kalyana-Sundaram, S.; Luo, S.; Khrebtukova, I.; Barrette, T.R.; Grasso, C.; Yu, J.; et al. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc. Natl. Acad. Sci. USA 2009, 106, 12353-12358.
34. Pflueger, D.; Rickman, D.S.; Sboner, A.; Perner, S.; LaFargue, C.J.; Svensson, M.A.; Moss, B.J.; Kitabayashi, N.; Pan, Y.; de la Taille, A.; et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 2009, 11, 804-811.
35. Attard, G.; Clark, J.; Ambroisine, L.; Mills, I.G.; Fisher, G.; Flohr, P.; Reid, A.; Edwards, S.; Kovacs, G.; Berney, D.; et al. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br. J. Cancer 2008, 99, 314-320.
36. Hermans, K.G.; van der Korput, H.A.; van Marion, R.; van de Wijngaart, D.J.; Ziel-van der Made, A.; Dits, N.F.; Boormans, J.L.; van der Kwast, T.H.; van Dekken, H.; Bangma, C.H.; et al. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res. 2008, 68, 7541-7549.
37. Hermans, K.G.; Bressers, A.A.; van der Korput, H.A.; Dits, N.F.; Jenster, G.; Trapman, J. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res. 2008, 68, 3094-3098.
38. Paulo, P.; Barros-Silva, J.D.; Ribeiro, F.R.; Ramalho-Carvalho, J.; Jeronimo, C.; Henrique, R.; Lind, G.E.; Skotheim, R.I.; Lothe, R.A.; Teixeira, M.R. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Gene. Chromosome. Cancer 2012, 51, 240-249.
39. Lapuk, A.V.; Wu, C.; Wyatt, A.W.; McPherson, A.; McConeghy, B.J.; Brahmbhatt, S.; Mo, F.; Zoubeidi, A.; Anderson, S.; Bell, R.H.; et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J. Pathol. 2012, 227, 286-297.
40. Nhili, R.; Peixoto, P.; Depauw, S.; Flajollet, S.; Dezitter, X.; Munde, M.M.; Ismail, M.A.; Kumar, A.; Farahat, A.A.; Stephens, C.E.; et al. Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines. Nucleic Acids Res. 2013, 41, 125-138.
41. Palanisamy, N.; Ateeq, B.; Kalyana-Sundaram, S.; Pflueger, D.; Ramnarayanan, K.; Shankar, S.; Han, B.; Cao, Q.; Cao, X.; Suleman, K.; et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med. 2010, 16, 793-798.
42. Beltran, H.; Yelensky, R.; Frampton, G.M.; Park, K.; Downing, S.R.; Macdonald, T.Y.; Jarosz, M.; Lipson, D.; Tagawa, S.T.; Nanus, D.M.; et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur. Urol. 2013, 63, 920-926.
43. Schaefer, G.; Mosquera, J.M.; Ramoner, R.; Park, K.; Romanel, A.; Steiner, E.; Horninger, W.; Bektic, J.; Ladurner-Rennau, M.; Rubin, M.A.; et al. Distinct ERG rearrangement prevalence in prostate cancer: Higher frequency in young age and in low PSA prostate cancer. Prostate Cancer Prostatic Dis. 2013, 16, 132-138.
44. Minner, S.; Enodien, M.; Sirma, H.; Luebke, A.M.; Krohn, A.; Mayer, P.S.; Simon, R.; Tennstedt, P.; Muller, J.; Scholz, L.; et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin. Cancer Res. 2011, 17, 5878-5888.
45. Attard, G.; Clark, J.; Ambroisine, L.; Fisher, G.; Kovacs, G.; Flohr, P.; Berney, D.; Foster, C.S.; Fletcher, A.; Gerald, W.L.; et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008, 27, 253-263.
46. Mehra, R.; Tomlins, S.A.; Yu, J.; Cao, X.; Wang, L.; Menon, A.; Rubin, M.A.; Pienta, K.J.; Shah, R.B.; Chinnaiyan, A.M. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 2008, 68, 3584-3590.
47. Stephens, P.J.; Greenman, C.D.; Fu, B.; Yang, F.; Bignell, G.R.; Mudie, L.J.; Pleasance, E.D.; Lau, K.W.; Beare, D.; Stebbings, L.A.; et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144, 27-40.
48. Baca, S.C.; Prandi, D.; Lawrence, M.S.; Mosquera, J.M.; Romanel, A.; Drier, Y.; Park, K.; Kitabayashi, N.; Macdonald, T.Y.; Ghandi, M.; et al. Punctuated evolution of prostate cancer genomes. Cell 2013, 153, 666-677.
49. Tomlins, S.A.; Laxman, B.; Varambally, S.; Cao, X.; Yu, J.; Helgeson, B.E.; Cao, Q.; Prensner, J.R.; Rubin, M.A.; Shah, R.B.; et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008, 10, 177-188.
50. King, J.C.; Xu, J.; Wongvipat, J.; Hieronymus, H.; Carver, B.S.; Leung, D.H.; Taylor, B.S.; Sander, C.; Cardiff, R.D.; Couto, S.S.; et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 2009, 41, 524-526.
51. Carver, B.S.; Tran, J.; Gopalan, A.; Chen, Z.; Shaikh, S.; Carracedo, A.; Alimonti, A.; Nardella, C.; Varmeh, S.; Scardino, P.T.; et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature Genet. 2009, 41, 619-624.
52. Casey, O.M.; Fang, L.; Hynes, P.G.; Abou-Kheir, W.G.; Martin, P.L.; Tillman, H.S.; Petrovics, G.; Awwad, H.O.; Ward, Y.; Lake, R.; et al. TMPRSS2-driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. PLoS One 2012, 7, e41668.
53. Yu, J.; Yu, J.; Mani, R.S.; Cao, Q.; Brenner, C.J.; Cao, X.; Wang, X.; Wu, L.; Li, J.; Hu, M.; et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010, 17, 443-454.
54. Goh, C.L.; Schumacher, F.R.; Easton, D.; Muir, K.; Henderson, B.; Kote-Jarai, Z.; Eeles, R.A. Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J. Int. Med. 2012, 271, 353-365.
55. Robbins, C.M.; Tembe, W.A.; Baker, A.; Sinari, S.; Moses, T.Y.; Beckstrom-Sternberg, S.; Beckstrom-Sternberg, J.; Barrett, M.; Long, J.; Chinnaiyan, A.; et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 2011, 21, 47-55.
56. Kumar, A.; White, T.A.; MacKenzie, A.P.; Clegg, N.; Lee, C.; Dumpit, R.F.; Coleman, I.; Ng, S.B.; Salipante, S.J.; Rieder, M.J.; et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl. Acad. Sci. USA 2011, 108, 17087-17092.
57. Spans, L.; Atak, Z.K.; van Nieuwerburgh, F.; Deforce, D.; Lerut, E.; Aerts, S.; Claessens, F. Variations in the exome of the lncap prostate cancer cell line. Prostate 2012, 72, 1317-1327.
58. Barbieri, C.E.; Baca, S.C.; Lawrence, M.S.; Demichelis, F.; Blattner, M.; Theurillat, J.P.; White, T.A.; Stojanov, P.; van Allen, E.; Stransky, N. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 2012, 44, 685-689.
59. Leach, F.S.; Velasco, A.; Hsieh, J.T.; Sagalowsky, A.I.; McConnell, J.D. The mismatch repair gene hMSH2 is mutated in the prostate cancer cell line LNCaP. J. Urol. 2000, 164, 1830-1833.
60. Chen, Y.; Wang, J.; Fraig, M.M.; Metcalf, J.; Turner, W.R.; Bissada, N.K.; Watson, D.K.; Schweinfest, C.W. Defects of DNA mismatch repair in human prostate cancer. Cancer Res. 2001, 61, 4112-4121.
61. Imamura, Y.; Sakamoto, S.; Endo, T.; Utsumi, T.; Fuse, M.; Suyama, T.; Kawamura, K.; Imamoto, T.; Yano, K.; Uzawa, K.; et al. Foxa1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway. PLoS One 2012, 7, e42456.
62. Sahu, B.; Laakso, M.; Ovaska, K.; Mirtti, T.; Lundin, J.; Rannikko, A.; Sankila, A.; Turunen, J.P.; Lundin, M.; Konsti, J.; et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 2011, 30, 3962-3976.
63. Makinen, N.; Mehine, M.; Tolvanen, J.; Kaasinen, E.; Li, Y.; Lehtonen, H.J.; Gentile, M.; Yan, J.; Enge, M.; Taipale, M.; et al. Med12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 2011, 334, 252-255.
64. Taatjes, D.J. The human mediator complex: A versatile, genome-wide regulator of transcription. Trends Biochem. Sci. 2010, 35, 315-322.
65. Majumder, P.K.; Grisanzio, C.; O'Connell, F.; Barry, M.; Brito, J.M.; Xu, Q.; Guney, I.; Berger, R.; Herman, P.; Bikoff, R.; et al. A prostatic intraepithelial neoplasia-dependent p27kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008, 14, 146-155.
66. Li, C.; Ao, J.; Fu, J.; Lee, D.F.; Xu, J.; Lonard, D.; O'Malley, B.W. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene 2011, 30, 4350-4364.
67. Natarajan, T.G.; Kallakury, B.V.; Sheehan, C.E.; Bartlett, M.B.; Ganesan, N.; Preet, A.; Ross, J.S.; Fitzgerald, K.T. Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon. Cancer Cell Int. 2010, 10, doi:10.1186/1475-2867-10-13.
68. Blazek, D.; Kohoutek, J.; Bartholomeeusen, K.; Johansen, E.; Hulinkova, P.; Luo, Z.; Cimermancic, P.; Ule, J.; Peterlin, B.M. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 2011, 25, 2158-2172.
69. Lindberg, J.; Mills, I.G.; Klevebring, D.; Liu, W.; Neiman, M.; Xu, J.; Wikstrom, P.; Wiklund, P.; Wiklund, F.; Egevad, L.; et al. The mitochondrial and autosomal mutation landscapes of prostate cancer. Eur. Urol. 2013, 63, 702-708.
70. Lindberg, J.; Klevebring, D.; Liu, W.; Neiman, M.; Xu, J.; Wiklund, P.; Wiklund, F.; Mills, I.G.; Egevad, L.; Gronberg, H. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur. Urol. 2013, 63, 347-353.
71. Menon, R.; Deng, M.; Boehm, D.; Braun, M.; Fend, F.; Boehm, D.; Biskup, S.; Perner, S. Exome enrichment and SOLiD sequencing of formalin fixed paraffin embedded (FFPE) prostate cancer tissue. Int. J. Mol. Sci. 2012, 13, 8933-8942.
72. MacInnis, R.J.; Antoniou, A.C.; Eeles, R.A.; Severi, G.; Guy, M.; McGuffog, L.; Hall, A.L.; O'Brien, L.T.; Wilkinson, R.A.; Dearnaley, D.P.; et al. Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies. Genet. Epidemiol. 2010, 34, 42-50.
73. Lichtenstein, P.; Holm, N.V.; Verkasalo, P.K.; Iliadou, A.; Kaprio, J.; Koskenvuo, M.; Pukkala, E.; Skytthe, A.; Hemminki, K. Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 2000, 343, 78-85.
74. Zhang, X.; Cowper-Sal lari, R.; Bailey, S.D.; Moore, J.H.; Lupien, M. Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus. Genome Res. 2012, 22, 1437-1446.
75. Eeles, R.A.; Olama, A.A.; Benlloch, S.; Saunders, E.J.; Leongamornlert, D.A.; Tymrakiewicz, M.; Ghoussaini, M.; Luccarini, C.; Dennis, J.; Jugurnauth-Little, S.; et al. Identification of 23 new prostate cancer susceptibility loci using the icogs custom genotyping array. Nat. Genet. 2013, 45, 385-391.
76. Jin, G.; Sun, J.; Isaacs, S.D.; Wiley, K.E.; Kim, S.T.; Chu, L.W.; Zhang, Z.; Zhao, H.; Zheng, S.L.; Isaacs, W.B.; et al. Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk. Carcinogenesis 2011, 32, 1655-1659.
77. Ahmadiyeh, N.; Pomerantz, M.M.; Grisanzio, C.; Herman, P.; Jia, L.; Almendro, V.; He, H.H.; Brown, M.; Liu, X.S.; Davis, M.; et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc. Natl. Acad. Sci. USA 2010, 107, 9742-9746.
78. Whitaker, H.C.; Kote-Jarai, Z.; Ross-Adams, H.; Warren, A.Y.; Burge, J.; George, A.; Bancroft, E.; Jhavar, S.; Leongamornlert, D.; Tymrakiewicz, M.; et al. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One 2010, 5, e13363.
79. Whitaker, H.C.; Warren, A.Y.; Eeles, R.; Kote-Jarai, Z.; Neal, D.E. The potential value of microseminoprotein-β as a prostate cancer biomarker and therapeutic target. Prostate 2010, 70, 333-340.
80. Cramer, S.D.; Chang, B.L.; Rao, A.; Hawkins, G.A.; Zheng, S.L.; Wade, W.N.; Cooke, R.T.; Thomas, L.N.; Bleecker, E.R.; Catalona, W.J.; et al. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J. Nat. Cancer Ins. 2003, 95, 1044-1053.
81. Severi, G.; Hayes, V.M.; Neufing, P.; Padilla, E.J.; Tilley, W.D.; Eggleton, S.A.; Morris, H.A.; English, D.R.; Southey, M.C.; Hopper, J.L.; et al. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 1142-1147.
82. Kote-Jarai, Z.; Saunders, E.J.; Leongamornlert, D.A.; Tymrakiewicz, M.; Dadaev, T.; Jugurnauth-Little, S.; Ross-Adams, H.; Al Olama, A.A.; Benlloch, S.; Halim, S.; et al. Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum. Mol. Genet. 2013, doi:10.1093/hmg/ddt086.
83. Jin, G.; Lu, L.; Cooney, K.A.; Ray, A.M.; Zuhlke, K.A.; Lange, E.M.; Cannon-Albright, L.A.; Camp, N.J.; Teerlink, C.C.; Fitzgerald, L.M.; et al. Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: Evidence from the international consortium for prostate cancer genetics (ICPCG). Hum. Genet. 2012, 131, 1095-1103.
84. Amin Al Olama, A.; Kote-Jarai, Z.; Schumacher, F.R.; Wiklund, F.; Berndt, S.I.; Benlloch, S.; Giles, G.G.; Severi, G.; Neal, D.E.; Hamdy, F.C.; et al. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum. Mol. Genet. 2013, 22, 408-415.
85. FitzGerald, L.M.; Kwon, E.M.; Conomos, M.P.; Kolb, S.; Holt, S.K.; Levine, D.; Feng, Z.; Ostrander, E.A.; Stanford, J.L. Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol. Biomark. Prev. 2011, 20, 1196-1203.
86. Duggan, D.; Zheng, S.L.; Knowlton, M.; Benitez, D.; Dimitrov, L.; Wiklund, F.; Robbins, C.; Isaacs, S.D.; Cheng, Y.; Li, G.; et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J. Natl. Cancer Inst. 2007, 99, 1836-1844.
87. Kote-Jarai, Z.; Olama, A.A.; Giles, G.G.; Severi, G.; Schleutker, J.; Weischer, M.; Campa, D.; Riboli, E.; Key, T.; Gronberg, H.; et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat. Genet. 2011, 43, 785-791.
88. Gudmundsson, J.; Sulem, P.; Rafnar, T.; Bergthorsson, J.T.; Manolescu, A.; Gudbjartsson, D.; Agnarsson, B.A.; Sigurdsson, A.; Benediktsdottir, K.R.; Blondal, T.; et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat. Genet. 2008, 40, 281-283.
89. Eeles, R.A.; Kote-Jarai, Z.; Al Olama, A.A.; Giles, G.G.; Guy, M.; Severi, G.; Muir, K.; Hopper, J.L.; Henderson, B.E.; Haiman, C.A.; et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet. 2009, 41, 1116-1121.
90. Schumacher, F.R.; Berndt, S.I.; Siddiq, A.; Jacobs, K.B.; Wang, Z.; Lindstrom, S.; Stevens, V.L.; Chen, C.; Mondul, A.M.; Travis, R.C.; et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum. Mol. Genet. 2011, 20, 3867-3875.
91. Eeles, R.A.; Kote-Jarai, Z.; Giles, G.G.; Olama, A.A.; Guy, M.; Jugurnauth, S.K.; Mulholland, S.; Leongamornlert, D.A.; Edwards, S.M.; Morrison, J.; et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 2008, 40, 316-321.
92. Gudmundsson, J.; Sulem, P.; Gudbjartsson, D.F.; Blondal, T.; Gylfason, A.; Agnarsson, B.A.; Benediktsdottir, K.R.; Magnusdottir, D.N.; Orlygsdottir, G.; Jakobsdottir, M.; et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat. Genet. 2009, 41, 1122-1126.
93. Thomas, G.; Jacobs, K.B.; Yeager, M.; Kraft, P.; Wacholder, S.; Orr, N.; Yu, K.; Chatterjee, N.; Welch, R.; Hutchinson, A.; et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 2008, 40, 310-315.
94. Al Olama, A.A.; Kote-Jarai, Z.; Giles, G.G.; Guy, M.; Morrison, J.; Severi, G.; Leongamornlert, D.A.; Tymrakiewicz, M.; Jhavar, S.; Saunders, E.; et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat. Genet. 2009, 41, 1058-1060.
95. Yeager, M.; Chatterjee, N.; Ciampa, J.; Jacobs, K.B.; Gonzalez-Bosquet, J.; Hayes, R.B.; Kraft, P.; Wacholder, S.; Orr, N.; Berndt, S.; et al. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat. Genet. 2009, 41, 1055-1057.
96. Haiman, C.A.; Patterson, N.; Freedman, M.L.; Myers, S.R.; Pike, M.C.; Waliszewska, A.; Neubauer, J.; Tandon, A.; Schirmer, C.; McDonald, G.J.; et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat. Genet. 2007, 39, 638-644.
97. Gudmundsson, J.; Sulem, P.; Manolescu, A.; Amundadottir, L.T.; Gudbjartsson, D.; Helgason, A.; Rafnar, T.; Bergthorsson, J.T.; Agnarsson, B.A.; Baker, A.; et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 2007, 39, 631-637.
98. Yeager, M.; Orr, N.; Hayes, R.B.; Jacobs, K.B.; Kraft, P.; Wacholder, S.; Minichiello, M.J.; Fearnhead, P.; Yu, K.; Chatterjee, N.; et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 2007, 39, 645-649.
99. Amundadottir, L.T.; Sulem, P.; Gudmundsson, J.; Helgason, A.; Baker, A.; Agnarsson, B.A.; Sigurdsson, A.; Benediktsdottir, K.R.; Cazier, J.B.; Sainz, J.; et al. A common variant associated with prostate cancer in european and african populations. Nat. Genet. 2006, 38, 652-658.
100. Chung, C.C.; Ciampa, J.; Yeager, M.; Jacobs, K.B.; Berndt, S.I.; Hayes, R.B.; Gonzalez-Bosquet, J.; Kraft, P.; Wacholder, S.; Orr, N.; et al. Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. Hum. Mol. Genet. 2011, 20, 2869-2878.
101. Sun, J.; Zheng, S.L.; Wiklund, F.; Isaacs, S.D.; Purcell, L.D.; Gao, Z.; Hsu, F.C.; Kim, S.T.; Liu, W.; Zhu, Y.; et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat. Genet. 2008, 40, 1153-1155.
102. Gudmundsson, J.; Sulem, P.; Steinthorsdottir, V.; Bergthorsson, J.T.; Thorleifsson, G.; Manolescu, A.; Rafnar, T.; Gudbjartsson, D.; Agnarsson, B.A.; Baker, A.; et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat. Genet. 2007, 39, 977-983.
103. Majumdar, S.; Buckles, E.; Estrada, J.; Koochekpour, S. Aberrant DNA methylation and prostate cancer. Curr. Genomics 2011, 12, 486-505.
104. Yegnasubramanian, S.; Haffner, M.C.; Zhang, Y.; Gurel, B.; Cornish, T.C.; Wu, Z.; Irizarry, R.A.; Morgan, J.; Hicks, J.; DeWeese, T.L.; et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 2008, 68, 8954-8967.
105. Lee, W.H.; Morton, R.A.; Epstein, J.I.; Brooks, J.D.; Campbell, P.A.; Bova, G.S.; Hsieh, W.S.; Isaacs, W.B.; Nelson, W.G. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 1994, 91, 11733-11737.
106. Shi, X.B.; Xue, L.; Ma, A.H.; Tepper, C.G.; Gandour-Edwards, R.; Kung, H.J.; Devere White, R.W. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene 2012, doi:10.1038/onc.2012.425.
107. Kron, K.; Pethe, V.; Briollais, L.; Sadikovic, B.; Ozcelik, H.; Sunderji, A.; Venkateswaran, V.; Pinthus, J.; Fleshner, N.; van der Kwast, T.; et al. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One 2009, 4, e4830.
108. Kim, S.J.; Kelly, W.K.; Fu, A.; Haines, K.; Hoffman, A.; Zheng, T.; Zhu, Y. Genome-wide methylation analysis identifies involvement of TNF-α mediated cancer pathways in prostate cancer. Cancer Lett. 2011, 302, 47-53.
109. Kim, Y.J.; Yoon, H.Y.; Kim, S.K.; Kim, Y.W.; Kim, E.J.; Kim, I.Y.; Kim, W.J. EFEMP1 as a novel DNA methylation marker for prostate cancer: Array-based DNA methylation and expression profiling. Clin. Cancer Res. 2011, 17, 4523-4530.
110. Kobayashi, Y.; Absher, D.M.; Gulzar, Z.G.; Young, S.R.; McKenney, J.K.; Peehl, D.M.; Brooks, J.D.; Myers, R.M.; Sherlock, G. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res. 2011, 21, 1017-1027.
111. Kim, J.H.; Dhanasekaran, S.M.; Prensner, J.R.; Cao, X.; Robinson, D.; Kalyana-Sundaram, S.; Huang, C.; Shankar, S.; Jing, X.; Iyer, M.; et al. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res. 2011, 21, 1028-1041.
112. Kim, J.W.; Kim, S.T.; Turner, A.R.; Young, T.; Smith, S.; Liu, W.; Lindberg, J.; Egevad, L.; Gronberg, H.; Isaacs, W.B.; et al. Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One 2012, 7, e48455.
113. Aryee, M.J.; Liu, W.; Engelmann, J.C.; Nuhn, P.; Gurel, M.; Haffner, M.C.; Esopi, D.; Irizarry, R.A.; Getzenberg, R.H.; Nelson, W.G.; et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci. Transl. Med. 2013, 5, doi: 10.1126/scitranslmed.3005211.
114. Borno, S.T.; Fischer, A.; Kerick, M.; Falth, M.; Laible, M.; Brase, J.C.; Kuner, R.; Dahl, A.; Grimm, C.; Sayanjali, B.; et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov. 2012, 2, 1024-1035.
115. Schwartzman, J.; Mongoue-Tchokote, S.; Gibbs, A.; Gao, L.; Corless, C.L.; Jin, J.; Zarour, L.; Higano, C.; True, L.D.; Vessella, R.L.; et al. A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. Epigenetics 2011, 6, 1248-1256.
116. Agell, L.; Hernandez, S.; Nonell, L.; Lorenzo, M.; Puigdecanet, E.; de Muga, S.; Juanpere, N.; Bermudo, R.; Fernandez, P.L.; Lorente, J.A.; et al. A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression. Am. J. Pathol. 2012, 181, 1585-1594.
117. Bismar, T.A.; Demichelis, F.; Riva, A.; Kim, R.; Varambally, S.; He, L.; Kutok, J.; Aster, J.C.; Tang, J.; Kuefer, R.; et al. Defining aggressive prostate cancer using a 12-gene model. Neoplasia 2006, 8, 59-68.
118. Sun, R.; Fu, X.; Li, Y.; Xie, Y.; Mao, Y. Global gene expression analysis reveals reduced abundance of putative microRNA targets in human prostate tumours. BMC Genomics 2009, 10, e93.
119. Volinia, S.; Calin, G.A.; Liu, C.G.; Ambs, S.; Cimmino, A.; Petrocca, F.; Visone, R.; Iorio, M.; Roldo, C.; Ferracin, M.; et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 2006, 103, 2257-2261.
120. Carlsson, J.; Davidsson, S.; Helenius, G.; Karlsson, M.; Lubovac, Z.; Andren, O.; Olsson, B.; Klinga-Levan, K. A miRNA expression signature that separates between normal and malignant prostate tissues. Cancer Cell Int. 2011, 11, e14.
121. Fuse, M.; Kojima, S.; Enokida, H.; Chiyomaru, T.; Yoshino, H.; Nohata, N.; Kinoshita, T.; Sakamoto, S.; Naya, Y.; Nakagawa, M.; et al. Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. J. Hum. Genet. 2012, 57, 691-699.
122. O'Kelly, F.; Marignol, L.; Meunier, A.; Lynch, T.H.; Perry, A.S.; Hollywood, D. MicroRNAs as putative mediators of treatment response in prostate cancer. Nat. Rev. Urol. 2012, 9, 397-407.
123. Ostling, P.; Leivonen, S.K.; Aakula, A.; Kohonen, P.; Makela, R.; Hagman, Z.; Edsjo, A.; Kangaspeska, S.; Edgren, H.; Nicorici, D.; et al. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res. 2011, 71, 1956-1967.
124. Shi, X.B.; Xue, L.; Yang, J.; Ma, A.H.; Zhao, J.; Xu, M.; Tepper, C.G.; Evans, C.P.; Kung, H.J.; deVere White, R.W. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc. Natl. Acad. Sci. USA 2007, 104, 19983-19988.
125. Ribas, J.; Ni, X.; Haffner, M.; Wentzel, E.A.; Salmasi, A.H.; Chowdhury, W.H.; Kudrolli, T.A.; Yegnasubramanian, S.; Luo, J.; Rodriguez, R.; et al. miR-21: An androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009, 69, 7165-7169.
126. Waltering, K.K.; Porkka, K.P.; Jalava, S.E.; Urbanucci, A.; Kohonen, P.J.; Latonen, L.M.; Kallioniemi, O.P.; Jenster, G.; Visakorpi, T. Androgen regulation of micro-RNAs in prostate cancer. Prostate 2011, 71, 604-614.
127. Gregory, P.A.; Bert, A.G.; Paterson, E.L.; Barry, S.C.; Tsykin, A.; Farshid, G.; Vadas, M.A.; Khew-Goodall, Y.; Goodall, G.J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biol. 2008, 10, 593-601.
128. Korpal, M.; Lee, E.S.; Hu, G.; Kang, Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 2008, 283, 14910-14914.
129. Park, S.M.; Gaur, A.B.; Lengyel, E.; Peter, M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008, 22, 894-907.
130. Tucci, P.; Agostini, M.; Grespi, F.; Markert, E.K.; Terrinoni, A.; Vousden, K.H.; Muller, P.A.; Dotsch, V.; Kehrloesser, S.; Sayan, B.S.; et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc. Natl. Acad. Sci. USA 2012, 109, 15312-15317.
131. Kong, D.; Li, Y.; Wang, Z.; Banerjee, S.; Ahmad, A.; Kim, H.R.; Sarkar, F.H. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009, 27, 1712-1721.
132. Peng, X.; Guo, W.; Liu, T.; Wang, X.; Tu, X.; Xiong, D.; Chen, S.; Lai, Y.; Du, H.; Chen, G.; et al. Identification of miRs-143 and-145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One 2011, 6, e20341.
133. Li, T.; Li, D.; Sha, J.; Sun, P.; Huang, Y. MicroRNA-21 directly targets marcks and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem. Biophys. Res. Commun. 2009, 383, 280-285.
134. Lee, Y.S.; Kim, H.K.; Chung, S.; Kim, K.S.; Dutta, A. Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J. Biol. Chem. 2005, 280, 16635-16641.
135. Spahn, M.; Kneitz, S.; Scholz, C.J.; Stenger, N.; Rudiger, T.; Strobel, P.; Riedmiller, H.; Kneitz, B. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int. J. Cancer.2010, 127, 394-403.
136. Selth, L.A.; Townley, S.; Gillis, J.L.; Ochnik, A.M.; Murti, K.; Macfarlane, R.J.; Chi, K.N.; Marshall, V.R.; Tilley, W.D.; Butler, L.M. Discovery of circulating micrornas associated with human prostate cancer using a mouse model of disease. Int. J. Cancer 2012, 131, 652-661.
137. Bussemakers, M.J.; van Bokhoven, A.; Verhaegh, G.W.; Smit, F.P.; Karthaus, H.F.; Schalken, J.A.; Debruyne, F.M.; Ru, N.; Isaacs, W.B. Dd3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999, 59, 5975-5979.
138. Wang, R.; Chinnaiyan, A.M.; Dunn, R.L.; Wojno, K.J.; Wei, J.T. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 2009, 115, 3879-3886.
139. Srikantan, V.; Zou, Z.; Petrovics, G.; Xu, L.; Augustus, M.; Davis, L.; Livezey, J.R.; Connell, T.; Sesterhenn, I.A.; Yoshino, K.; et al. Pcgem1, a prostate-specific gene, is overexpressed in prostate cancer. Proc. Natl. Acad. Sci. USA 2000, 97, 12216-12221.
140. Chung, S.; Nakagawa, H.; Uemura, M.; Piao, L.; Ashikawa, K.; Hosono, N.; Takata, R.; Akamatsu, S.; Kawaguchi, T.; Morizono, T.; et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci. 2011, 102, 245-252.
141. Cui, Z.; Ren, S.; Lu, J.; Wang, F.; Xu, W.; Sun, Y.; Wei, M.; Chen, J.; Gao, X.; Xu, C.; et al. The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urol. Oncol. 2012, doi:10.1016/j.urolonc.2011.11.030.
142. Prensner, J.R.; Iyer, M.K.; Balbin, O.A.; Dhanasekaran, S.M.; Cao, Q.; Brenner, J.C.; Laxman, B.; Asangani, I.A.; Grasso, C.S.; Kominsky, H.D.; et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat. Biotechnol. 2011, 29, 742-749.
143. Balk, S.P.; Knudsen, K.E. Ar, the cell cycle, and prostate cancer. Nucl. Recept. Signal. 2008, 6, e001.
144. Sharma, N.L.; Massie, C.E.; Ramos-Montoya, A.; Zecchini, V.; Scott, H.E.; Lamb, A.D.; MacArthur, S.; Stark, R.; Warren, A.Y.; Mills, I.G.; et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 2013, 23, 35-47.